Overview

T cell-based cancer immunotherapy has been a clinical breakthrough since 2013 (Science, 2013, 342, 6165). Lymphopoiesis-targeted therapy is still immature, but is of interest to multiple development programs. Currently IL-2 is the only common γ-chain cytokine available for T cell therapy. However, IL-2’s efficacy is limited by short persistence T cells, increased regulatory T cells, and over-activated NK cells. The weakness of IL-2’s efficacy and safety can be overcome with IL-7 by enhancing the expansion and functions of T cells to treat chronic virus infection and cancer.

Hyleukin, our lead product, is the fusion protein of engineered IL-7 and hyFc. It has a great potential to satisfy the unmet needs in the chronic infection and cancer markets by increasing the number, function and survival of T cells, compared to other common gamma chain cytokines, IL-2, IL-7, IL-15, and IL-21.

Category IL-7 IL-2
1 Caserta S et al. Eur J Immuno. 2010:40;470 2 Rosenberg SA et al. J Immunother. 2006:29;313
3 Levy Y et al. Clin Infect Dis. 2012:55;291 4 Rlorent Carrette et al. Seminars in Immunology. 2012:24;209
Persistency of produced T cell Long1 Short
% T reg / Total lymphocyte Decrease2 Increase
Thymus/Repertoire Thymopoietic activity TCR repertoire diversity3 No Action
Side Effects Self-regulation4 (IL-7R expression reduction) Over-activation NK cell stimulation
To install the latest Internet Explorer